Approximate Confidence Intervals for Probabilities of Survival and Quantiles in Life-Table Analysis

Anderson, James R.; Bernstein, Leslie; Pike, Malcolm C.

doi:10.2307/2530454

Cited by 71 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the response rates, the 95% CI was calculated as described previously. 20 The distribution of time to death from date of study entry was estimated using the KaplanMeier product-limit method. 21 …”

Section: Methodsmentioning

confidence: 99%

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma

Scheithauer

Kornek

Ulrich‐Pur

et al. 2001

Cancer

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma

Scheithauer

Kornek

Ulrich‐Pur

et al. 2001

Cancer

View full text Add to dashboard Cite

“…If at least one CR or PR was observed, > 30 patients were to be entered in the study to determine the response rate more accurately. For the response rates, 95% confidence intervals (CI) were calculated as previously described (Anderson et al, 1982). The distribution of TTP and time to death from the date of study entry were estimated using the Kaplan-Meier product-limit method (Kaplan and Meier, 1958).…”

Section: Methodsmentioning

confidence: 99%

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

et al. 1999

View full text Add to dashboard Cite

Although the novel cytidin analogue gemcitabine has shown superior anti-tumour activity than 5-fluorouracil in advanced pancreatic cancer, further improvements of therapeutic results are warranted. This goal might be achieved by combining gemcitabine with other active drugs. This trial evaluated the efficacy and tolerance of such a combination regimen with epirubicin and granulocyte colony-stimulating factor (G-CSF) in patients with metastatic disease. Seventy patients with metastatic pancreatic adenocarcinoma were enrolled in this multicentre trial. Patients received 4-weekly courses of a combination regimen consisting of epirubicin 60 mg m −2 given as intravenous bolus injection on day 1, gemcitabine 1000 mg m −2 infused over 30 min on days 1, 8 and 15, and G-CSF administered at 5 μg kg −1 day −1 subcutaneously from days 2–6 during each cycle. The efficacy of treatment was assessed by conventional measures, i.e. objective response, progression-free and overall survival, as well as by analysis of clinical benefit response (defined as ≥ 50% reduction in pain intensity, ≥ 50% reduction in daily analgesic consumption, and/or ≥ 20-point improvement in Karnofsky performance status that was sustained for ≥ 4 consecutive weeks). Of 66 patients evaluable for objective response, one achieved complete and 13 partial remissions, for an overall response rate of 21% (95% confidence interval (CI), 12–33%); 27 additional patients (41%) had stable and 25 (38%) increasing disease. The median time to progression was 3.8 months. Median survival was 7.8 months, and the probability of surviving beyond 12 months was 21.2%. Out of 60 patients with tumour-related symptoms, who were considered evaluable for clinical benefit response, 26 (43%) experienced significant palliation. The median time to achieve a clinical benefit response was 7 weeks, and its median duration was 22 weeks. Chemotherapy was well-tolerated with leukopenia/granulocytopenia representing the most common and dose-limiting side-effect. Gastrointestinal and other subjective toxicities were infrequent and generally rated minor. We conclude that the combination of gemcitabine, epirubicin and G-CSF seems to be an effective palliative treatment with only moderate toxic effects in patients with metastatic pancreatic adenocarcinoma. Our results in terms of objective and clinical benefit response, as well as survival seem to suggest an advantage over gemcitabine-monotherapy, though this remains to be confirmed in a randomized trial. © 1999 Cancer Research Campaign

show abstract

“…P-values were calculated from the student t-test and values 50.05 were considered significant. For overall response rate, 95% confidence intervals (CI) were calculated as described by Anderson et al, 1982. Time to response was measured from the first dose of chemotherapy to the onset of best response, duration of response was measured from the onset of the best response to the date of disease progression, and overall survival from the first dose of chemotherapy to the date of death.…”

Section: Statistical Analysesmentioning

confidence: 99%

Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

et al. 2002

View full text Add to dashboard Cite

The current role of chemotherapy in pancreatic carcinoma is limited, and progress in the treatment of this disease represents a significant challenge to medical oncology. The most promising drug under study is gemcitabine, a relatively new antimetabolite that represents an attractive candidate for combination chemotherapy because of its excellent side-effect profile and the absence of overlapping toxicities with other chemotherapeutic agents. Combined administration of gemcitabine and anthracyclines could result in the induction of DNA breaks that are not easily repaired by the cell's machinery, thus enhancing the apoptotic signals triggered by these lesions. Forty-four patients with locally advanced and/or metastatic pancreatic adenocarcinoma were enrolled in this multicenter study. Patients received Epirubicin 20 mg m 72 for 3 weeks followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m 72 after Epirubicin on the same day. All were assessable for toxicity and response, 11 patients responded to treatment with one complete response and 10 partial responses, for an overall response rate of 25%. Median survival was 10.9 months (range, 2 -26 months). Therapy was well tolerated, with a low incidence of haematologic grade 42 toxicity. A total of 12 of 27 (44.4%) eligible patients attained a clinical benefit response. Our findings suggest that the gemcitabine-epirubicin schedule is active and well tolerated in patients with advanced pancreatic cancer.

show abstract

Approximate Confidence Intervals for Probabilities of Survival and Quantiles in Life-Table Analysis

Cited by 71 publications

References 0 publications

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

Contact Info

Product

Resources

About